Cleven 4000 Anti-Xa IU/0.4 ml (SC Injection)
0.4 ml pre-filled syringe: ৳ 450.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Enoxaparin sodium |
| Company | Beximco pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of deep vein thrombosis, with or without pulmonary embolism
- Treatment of unstable angina and non-Q-wave myocardial infarction
- Prevention of thrombus formation in extra corporeal circulation during hemodialysis
- Prophylaxis of venous thromboembolic disease in surgical patients
- Prophylaxis of venous thromboembolic disease in medical patients
Composition
- Each 0.2 ml pre-filled syringe contains Enoxaparin Sodium BP 20 mg
- Each 0.4 ml pre-filled syringe contains Enoxaparin Sodium BP 40 mg
- Each 0.6 ml pre-filled syringe contains Enoxaparin Sodium BP 60 mg
- Each 0.8 ml pre-filled syringe contains Enoxaparin Sodium BP 80 mg
Pharmacology
Low molecular weight heparin with high anti-Xa activity and low anti-IIa or antithrombin activity
Dosage
- Subcutaneously 100 anti-Xa lU/kg twice daily for 10 days
- Subcutaneously 150 anti-Xa lU/kg once daily for 10 days
- Oral anticoagulant therapy recommended for deep vein thrombosis treatment
- Subcutaneously 100 anti-Xa lU/kg twice daily for 2-8 days for unstable angina and non-Q-wave myocardial infarction treatment
- Recommended dose for prevention of thrombus formation in hemodialysis
Administration
Instructions for self-injection of Enoxaparin Sodium Syringes
Interaction
Recommendation to discontinue agents affecting hemostasis prior to Cleven therapy
Contraindications
- Known hypersensitivity to Enoxaparin Sodium, heparin or other low molecular weight heparins
- Active major bleeding
- Conditions with a high risk of uncontrolled hemorrhage
Side Effects
- Haemorrhage (bleeding)
- Thrombocytopenia
- Elevations of serum aminotransferase
- Pain and bluish marks at injection sites
- Skin rash at injection sites
- Neuraxial hematomas with concurrent use of Cleven and spinal/epidural anesthesia
Pregnancy & Lactation
Enoxaparin Sodium pregnancy category B, no evidence of crossing placental barrier
Precautions & Warnings
- Administration by deep subcutaneous route
- Caution in conditions with increased potential for bleeding
- Recommended platelet count measurement before initiation of treatment
Use in Special Populations
- No dosage adjustment in elderly patients
- Observation for signs and symptoms of bleeding in renal impairment patients
- Caution in hepatically impaired patients
Overdose Effects
Accidental overdosage may lead to hemorrhagic complications, can be neutralized by protamine sulfate
Therapeutic Class
Parenteral anti-coagulants
Storage Conditions
Store in cool, dry place, protect from light and moisture, do not store above 25°C